EASTGATE BIOTECH CORP
Financials · Investors, NEC · NV · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY16 | FY15 | FY14 | FY13 | FY12 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | −$2.6M | −$4.2M | −$4.8M | −$1.7M | — |
| Net income | −$3.0M | −$4.3M | −$4.9M | −$1.7M | −$622,820 |
| Total assets | $0 | $297,919 | $482,935 | $71,755 | $104,500 |
| Total liabilities | $4.6M | $2.8M | $1.9M | $2.4M | — |
| Equity | −$4.6M | −$2.5M | −$1.4M | −$2.3M | −$609,008 |
| EPS (diluted) | — | — | — | — | — |
| Shares out. | 306.8M | 125.4M | 89.6M | 43.7M | 31.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2016- Operating margin
- —
- Net margin
- —
- Return on equity
- 64.5%
- Return on assets
- —
- Return on capital (ROCE)
- —
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-0.02
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 1 good- Negative shareholder equity
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Strong return on equity (>15%)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 30, 2016
- NT 10-Qmissed a reporting deadline ↗Nov 16, 2015
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2015
- NT 10-Qmissed a reporting deadline ↗May 15, 2015
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2015
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2014
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Director / officer changeSep 16, 2019
- Changed auditorJun 8, 2018
- Entered a material agreement · Unregistered equity saleMay 7, 2018
- Entered a material agreement · Unregistered equity saleMay 22, 2017
- Changed auditor · Prior financials not reliable (restatement)May 16, 2017
- Entered a material agreement · Delisting / listing-standard noticeMay 1, 2017
- Entered a material agreementDec 19, 2016
- Unregistered equity saleJun 1, 2015
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-K8K EASTGATE BIOTECH - 09.04.19Sep 16, 2019
- 15-12GFORM 15Aug 2, 2019
- 10-QCONVERTED BY EDGARWIZMar 4, 2019
- 10-QEASTGAT BIOTECH - 10Q -JUNE 30, 2017 - Q2Dec 18, 2018
- 10-Q/AFORM 10Q/A - 03/31/17 - EASTLAND BIOTECHNOLOGY CORP.Aug 17, 2018
- 10-QFORM 10Q - 03/31/17 - EASTLAND BIOTECHNOLOGY CORP.Aug 17, 2018
- 8-K8K - EASTGATE - CHANGE IN AUDITOR - 06.01.18Jun 8, 2018
- 8-K8-K EASTGATE MAY 4, 2018May 7, 2018
- 10-Q/AFORM 10-Q/AMar 1, 2018
- 10-Q/AFORM 10-QMar 1, 2018
- 10-Q/AFORM 10-Q/AMar 1, 2018
- 10-KFORM 10-KMar 1, 2018
- 8-K/AFORM 8-K/AMay 25, 2017
- 8-KFORM 8-KMay 22, 2017
- 8-KFORM 8-KMay 16, 2017
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.